Bloomington, Ind. – Cook Medical and Surmodics, Inc. are proud to announce a new agreement in which Cook Medical will distribute two new Surmodics products, hydrophilic percutaneous transluminal angioplasty (PTA) balloon catheters that can be used over 0.014-inch and a 0.018-inch wire guides.
“We’ve had a long relationship with Surmodics, utilizing its innovative surface modification technology with many of our other vascular products. Now, we are excited to expand on this partnership by adding these two Surmodics-designed PTA catheters to our existing vascular solutions portfolio. Most importantly, this will give physicians even more options to treat patients suffering from peripheral artery disease (PAD),” said Mark Breedlove, vice president of Cook Medical’s Vascular division.
The new balloon catheters, which will launch in the US later in 2020, can be used to help patients who are suffering from below-the-knee critical limb ischemia.
About Surmodics
Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic (IVD) immunoassay tests and microarrays. In addition, Surmodics is developing highly differentiated medical devices by combining the Company’s expertise in proprietary surface technologies, along with advanced device design, development and manufacturing capabilities. The Company mission remains to improve the detection and treatment of disease. Surmodics is headquartered in Eden Prairie, Minnesota. For more information, visit www.surmodics.com.
About Cook Medical
Since 1963, Cook Medical has been inventing, manufacturing, and delivering a unique portfolio of medical devices to healthcare systems around the world. We work closely with physicians to develop technologies that improve patients’ lives. Because we remain family owned, we have the freedom to focus on what we care about: our patients, our employees, and our communities. Find out more at CookMedical.com, and for the latest news, follow us on Twitter, Facebook and LinkedIn.